JOURNAL of
ONCOLOGICAL
SCIENCES

ORIGINAL RESEARCH ARTICLE

Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study
Received Date : 26 Mar 2020
Accepted Date : 23 Jun 2020
Available Online : 14 Jul 2020
Doi: 10.37047/jos.2020-75080 - Article's Language: EN
J Oncol Sci.2020;6(2):87-95
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Objective: The study aimed to evaluate the efficacy of targeted therapies used as the third-line treatment after first-line cytokine and second-line tyrosine kinase inhibitor (TKI) therapies in metastatic renal cell carcinoma (mRCC) patients and assess the quality of life (QoL) of patients. Material and Methods: This national, multicenter, non-interventional study included patients aged ≥18 years with histologically confirmed mRCC, receiving targeted therapies as the third-line treatment for the last one month. Overall survival (OS), progression-free survival (PFS), adverse events (AEs), and QoL were evaluated. Results: The study included 102 mRCC patients (74 males) (median age of 61 years). The median disease duration since diagnosis was 27.5 months (ranging 4-201 months). Of all the patients, 75.5% and 24.5% were receiving Axitinib and Everolimus, respectively, as third-line therapy. In all patients, the one-year PFS and OS rates were 62.9% and 79.9%, respectively. Seventy-one AEs (mostly mild) developed in 29 (28.4%) patients, fatigue being the most common (9.8%) AE. As compared to the baseline, no significant change was observed in the QoL scores of patients in the 12th month. The Axitinib and Everolimus groups did not differ significantly as regards to PFS and OS. Of the 11 patients with grade III-IV AEs, four were from the Everolimus group, and seven belonged to the Axitinib group. The QoL scores did not show a significant difference between the two groups except for that in the 12th month. Conclusion: Third-line therapy in mRCC patients was found to be effective and tolerable. Prolonged survival in mRCC patients receiving an increasing number of therapy lines requires further evaluation of QoL, considering it to be a part of treatment assessment.
KAYNAKLAR
  1. Rossi SH, Klatte T, Usher-Smith J, Stewart GD. Epidemiology and screening for renal cancer. World J Urol. 2018;36(9):1341-1353. [Crossref]  [PubMed]  [PMC] 
  2. Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. November 2014;349:g4797. [Crossref]  [PubMed]  [PMC] 
  3. Zerdes I, Tolia M, Tsoukalas N, et al. Systemic therapy of metastatic renal cell carcinoma: review of the current literature. Urologia. 2019;86(1):3-8. [Crossref]  [PubMed] 
  4. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist. 2011;16(Suppl 2): 14-22. [Crossref]  [PubMed] 
  5. Larriba JLG, Espinosa E, Carbonero IG, et al. Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer Metastasis Rev. 2012;31(suppl 1):S11-17. [Crossref]  [PubMed] 
  6. Bedke J, Gauler T, Grünwald V, et al. Systemic therapy in metastatic renal cell carcinoma. World J Urol. 2017;35(2):179-188. [Crossref]  [PubMed] 
  7. Cella D, Yount S, Du H, et al. Development and validation of the functional assessment of cancer therapy-kidney symptom index (FKSI). J Support Oncol. 2006;4(4):191-199. [PubMed] 
  8. Cella D, Yount S, Brucker PS, et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health. 2007;10(4):285-293. [Crossref]  [PubMed] 
  9. Euroqol. EQ-5D instruments. https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/ Accessed 02 August 2019.
  10. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase3 trial. Lancet Oncol. 2013;14(6):552-562. [Crossref]  [PubMed] 
  11. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939. [Crossref]  [PubMed] 
  12. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-456. [Crossref]  [PubMed] 
  13. Guida A, Albiges L, Derosa L, et al. Everolimus versus Axitinib as second-line therapy in metastatic renal cell carcinoma: experience from institut gustave roussy. Clin Genitourin Cancer. 2017;15(6):e1081-1088. [Crossref]  [PubMed] 
  14. Vogelzang NJ, Pal SK, Signorovitch JE, et al. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. Curr Med Res Opin. 2016;32(4):741-747. [Crossref]  [PubMed] 
  15. Procopio G, Verzoni E, Iacovelli R, et al. Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. Br J Cancer. 2012;107(8):1227-1232. [Crossref]  [PubMed]  [PMC] 
  16. Fischer S, Gillessen S, Rothermundt C. Sequence of treatment in locally advanced and metastatic renal cell carcinoma. TranslAndrol Urol. 2015;4(3):310-325. [PubMed] 
  17. Harada K, Nozawa M, Uemura M, et al. Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan. Int J Urol. 2019;26(2):202-210. [Crossref]  [PubMed] 
  18. Wells JC, Stukalin I, Norton C, et al. Third-line targeted therapy in metastatic renal cell Carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur Urol. 2017;71(2):204-209. [Crossref]  [PubMed] 
  19. Lambea J, Hinojo C, Lainez N, et al. Quality of life and supportive care for patients with metastatic renal cell carcinoma. Cancer Metastasis Rev. 2012;31(Suppl1):S33-39. [Crossref]  [PubMed] 
  20. Cella D. Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. Oncologist. 2011;16(Suppl2):23-31. [Crossref]  [PubMed] 
  21. Carmichael C, Yuh BE, Sun V, et al. Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors. Clin Genitourin Cancer. 2013;11(2):149-154. [Crossref]  [PubMed]  [PMC] 
  22. Miyake H, Harada KI, Ozono S, Fujisawa M. Assessment of efficacy, safety, and quality of life of 124 patients treated with axitinib as second-line therapy for metastatic renal-cell carcinoma: experience in real-world clinical practice in Japan. Clin Genitourin Cancer. 2017;15(1):122-128. [Crossref]  [PubMed] 
  23. Trask PC, Bushmakin AG, Cappelleri JC, Bycott P, Liau K, Kim S. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol. 2008;47(5):843-851. [Crossref]  [PubMed] 
  24. Goebell PJ, Hermann E, Kube U, et al. Final results of a non-interventional study evaluating the quality of life in second-line treatment of metastatic renal cell carcinoma with everolimus: The everpro Study. Oncol Res Treat. 2019;42(1-2):57-66. [Crossref]  [PubMed] 
  25. Cella D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev. 2009;35(8):733-737. [Crossref]  [PubMed] 
  26. Ishihara H, Takagi T, Kondo T, et al. Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. Int J Clin Oncol. 2018;23(3):559-567. [Crossref]  [PubMed] 
  27. de Groot S, Redekop WK, Versteegh MM, et al. Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Qual Life Res. 2018;27(1):115-124. [Crossref]  [PubMed]  [PMC] 
  28. Di Lorenzo G, Scagliarini S, Di Napoli M, Scognamiglio F, Rizzo M, Carteni G. Targeted therapy in the treatment of metastatic renal cell cancer. Oncology. 2009;77(Suppl1):122-131. [Crossref]  [PubMed]